To identify differentially expressed genes between relapsed and non-relapsed clinical stage I testicular germ cell tumours (TGCTs).
Introduction
Testicular germ cell tumour (TGCT) is the most common solid neoplasm affecting men aged between 15 and 40 years [1] , and the incidence has doubled over the last 30 years [2] . During this time, management has changed significantly with the advent of cisplatin-based chemotherapy. Remarkably, >80% of all patients with TGCT are cured across all stages [3] . With highly effective therapy available for patients who relapse, active surveillance is a widely adopted approach to clinical stage I TGCT. Our institutional practice at the Princess Margaret Cancer Centre has been to offer active surveillance to all patients with clinical stage I seminoma (SGCTs) and non-seminoma germ cell tumours (NSGCTs) using a standardized schedule [4, 5] . Although adjuvant treatment reduces the chance of relapse in clinical stage I SGCTs (15-20% to~5%) and NSGCTs (50% to 5-10% in Stage Ib), cure rates for patients managed with active surveillance approach 100% [4] and avoids overtreatment for those who would not have otherwise relapsed.
Active surveillance for clinical stage I disease relies on patient adherence to the surveillance schedule and fitness to tolerate treatment at relapse, which may include retroperitoneal lymph node dissection, radiation or three or four cycles of bleomycin/etoposide/cisplatin chemotherapy. This approach involves frequent CT scans, which may carry an increased risk of secondary cancers [6] and is anxiety-provoking for patients in the setting of intensive surveillance. Given the expected high cure rates, it is important to minimize the potential harms associated with surveillance approaches. Identification of a subset of patients within the clinical stage I population who are potentially at highest risk of relapse could permit the selection of those most likely to benefit from adjuvant treatment. Poor prognostic factors have been identified in clinical stage I TGCT, such as tumour size >4 cm in SGCTs [5] and lymphovascular invasion, pathological stage and/or embryonal histology [7, 8] in NSGCTs, which increases the risk of relapse to~20% in SGCTs and 50% in NSGCTs. Adjuvant therapy with carboplatin area under the curve 7 9 1 or bleomycin/ etoposide/cisplatin 9 1-2 cycles for 'high-risk' patients leads to overtreatment in~80% and 50%, respectively, using standard high-risk features. Molecular markers, such as gene expression analysis, may be complementary to standard pathological risk evaluation, and may refine prognostication or identify patients who might be most appropriate for a riskadapted approach. In addition, these markers may identify potential novel therapeutic targets. The aim of the present study, therefore, was to determine a differentiating gene expression pattern between those with relapsed and nonrelapsed clinical stage I TGCTs treated with active surveillance.
Materials and Methods

Case Selection
In this retrospective study, we reviewed patients diagnosed with clinical stage I TGCT between 2000 and 2012 at the Princess Margaret Cancer Centre. Patients were identified from an institutional testicular cancer database (eCancerCare Testis ) after research ethics board approval had been obtained. All patients provided consent for use of their tumour tissue for research. Patients were included if they were diagnosed with clinical stage I TGCT (SGCT or NSGCT), had archival orchiectomy testicular tumour tissue available, and were managed with active surveillance. Relapse was identified by unequivocal tumour marker rise and/or new metastases on imaging. Patients with NSGCT with enlarging retroperitoneal nodal metastases on relapse, who underwent primary retroperitoneal lymph node dissection and were found to have mature teratoma or negative nodes were excluded. Non-relapsed SGCTs and NSGCTs required a minimum follow-up of 3 and 2 years, respectively, to be considered relapse-free. Patients were excluded if they received adjuvant therapy.
Clinical Data
Clinical data were collected from the institutional testis database and electronic medical records. Data collected included baseline tumour characteristics, tumour markers and relapse characteristics.
Tissue Handling
All samples had pathology review for histological subtyping. Six slides were cut from paraffin-embedded testicular tumour tissue and then macro-dissected to identify appropriate tumour tissue for RNA extraction. RNA was extracted using the Roche High Pure FFPE RNA micro kit (Roche, Basel, Switzerland). Extractions were carried out as per the manufacturer's recommendations.
Gene Expression Analysis
Two hundred nanograms of tumour RNA were labelled and amplified after using an Illumina Whole Genome-DASL Assay kit (Illumina Inc., San Diego, CA, USA) for partially degraded and formalin-fixed paraffin-embedded derived RNA samples. Libraries were prepared as per the Illumina BeadChip process (Appendix S1). The labelled samples were then hybridized onto four Human HT-12 V4 BeadChips. The BeadChips were incubated at 58°C, for 18 h with rotation speed 5 in an Illumina hybridization oven for hybridization. The BeadChips were then washed and coated as per Illumina protocol and scanned on the iScan (Illumina). The data files were quantified in GenomeStudio Version 2011.1 (Illumina). All samples passed Illumina's sample dependent and independent controls.
We performed gene-set enrichment analysis (GSEA) [9] to identify the GeneOntology biological processes (MSIGDB C5 collection version 5.1) enriched in genes significantly associated with pathological complete response or disease type (Appendix S1).
Predictive Signature
We attempted to build a predictive gene signature capable of classifying the samples as 'responder' and 'non-responder' classes. First, we rank-ordered the genes according to their significance, obtained by fitting the data to a generalized linear model (using glm function in R). Next, we selected the top 10, 30 and 100 most significant genes. Predictive models were built based on these three signatures, and each model was validated through 10-fold cross validation [10] . Prediction scores were computed using the 'sig.score' function from the 'genefu' package [11] and statistically compared using the Wilcoxon rank sum test.
Statistical Analysis
Data are represented as log2 ratios for the expression analysis of gene transcriptions. Wilcoxon testing was used to separate non-relapsed and relapsed samples for differential expression. Hierarchical clustering analysis was used to present gene expression patterns. All reported P values are two-sided and P values <0.05 were considered statistically significant. All analysis was conducted using R version 2. 
Results
In total, 57 patients were selected based on available tissue (15 relapsed seminomas and 12 relapsed NSGCTs matched with 15 non-relapsed seminomas and 15 non-relapsed NSGCTs as controls). The baseline demographics of these patients are shown in Table 1 . In total, 12 relapsed NSGCTs, 15 relapsed seminomas, 15 non-relapsed NSGCTs and 15 non-relapsed seminoma cases were included. The median (range) times to relapse after surgery in the relapsed NSGCT and relapsed seminoma cohorts were 5.6 (2.5-18.1) and 19.3 (4.7-65.3) months, respectively. Poor prognostic factors were more frequent in relapsed vs non-relapsed cases (nonseminoma: vascular invasion 5/12 vs 0/15; seminoma: median size 4 vs 2.8 cm).
Hierarchical Clustering
A total of 29 377 probes were represented on the DASL gene expression analysis. Data were first filtered to remove the confounding effect of probes that showed no signal. Only probes that were above the 25th percentile of the distribution of intensities in 75% of any one of the four groups (relapsed NSGCT, relapsed seminoma, non-relapsed NSGCT, nonrelapsed seminoma) were allowed to pass through this filtering. The final set contained 20 819 probes, with the top 1 000 probes shown in Fig. 1 , annotated according to the four clinical subgroups of patients. An unsupervised clustering using a Euclidean measure as a distance metric, with complete linkage rules in the tree -building algorithm of this set of probes, was assessed. Using Wilcoxon's test with a Benjamini-Hochberg false discovery rate-corrected P value <0.05 showed 1 039 differentially expressed genes between relapsed and non-relapsed disease (Fig. 2) .
Gene-Set Enrichment Analysis
We conducted GSEA to identify discriminating biological pathways associated differentially between relapsed and nonrelapsed disease, and seminoma from non-seminoma. Pathways enriched at a false discovery rate of <0.05 are shown in Fig. 3 . There was overall concordance between sets that discriminated relapsed from non-relapsed disease and seminoma from non-seminoma apart from a single pathway. In the seminona vs non-seminoma setting, 48 gene sets were enriched (upregulated, n = 8; downregulated, n = 40) whilst in the relapsed vs non-relapsed setting, 12 gene sets were enriched (upregulated, n = 4; downregulated, n = 8).
Genes associated with active development and differentiation were particularly enriched in patients with relapsed disease such as skeletal development (i.e. FGFR1, BMP4, GLI2, SPARC, COL2A1), tissue (i.e. BMP4, SPARC, COL13A1,) and bone remodelling (i.e. CARTPT, GLI2, MGP). Similarly, pathways that discriminated seminoma from non-seminoma were predominantly related to differentiation pathways, such as nervous system, skeletal muscle, ectoderm and epidermis development.
The top 10 genes associated with delineating relapsed from non-relapsed disease and seminoma from non-seminoma are shown in Table 2 . Notably, genes associated with increased tumorigenesis showed high levels of fold change when discriminating relapsed from non-relapsed disease (e.g. EPHA10 [log fold change 1.20] 
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© 2018 The Authors BJU International © 2018 BJU International retrovirus WE1; log fold change 0.50, adjusted P < 0.001). Similarly, TCL1A (T-cell leukaemia/lymphoma 1A; log fold change 0.41, adjusted P < 0.001), which augments protein kinase B (AKT) signal transduction, was upregulated in seminoma [12] .
Gene Expression Signature
A gene expression signature was developed to compare nonrelapsed with relapsed disease (Fig. S1 ). Sixteen probes in SGCT and 653 probes in NSGCT were identified using post hoc Tukey's honest significant difference test. A discriminative gene expression signature between relapsed and non-relapsed cases was discovered when combining non-seminoma and seminoma samples using 10-probe (P = 0.03) and 30-probe (P = 0.03) signatures with a 10-fold cross-validation (Fig. 4) ; however, this profile was not observed in the cohorts when separated individually. In SGCT, a 10-probe (P = 0.12) and 100-probe (P = 0.09) signature trended towards significance. In NSGCT, a 10-(P = 0.36), 30-(P = 0.31) or 100-probe (P = 0.36) signature showed no statistical significance.
Discussion
Despite cure rates approaching 100% in clinical stage I TGCT with active surveillance and treatment on relapse [4] , management has evolved for those at high risk of relapse. Given that orchiectomy will cure the majority of patients with clinical stage I TGCT, prediction algorithms that use pathological risk assessment have been used to select patients who are most likely to benefit from adjuvant therapy. For example, in NSGCT, relapse risk is associated with lymphovascular invasion and or embryonal carcinoma in the primary tumour [7, 8] . Similarly, tumour size >4 cm [5, 13] in SGCT is associated with a higher chance of relapse. Even accounting for these risk factors, adjuvant chemotherapy in clinical stage I TGCT leads to overtreatment in up to 80% of patients in SGCT and 50% in NSGCT; thus, integration of novel prognostic markers might identify patients with a higher relapse risk, where the probability of overtreatment with adjuvant therapy is reduced.
More recently, the biological underpinnings of TGCT have been investigated. Genome-wide association studies have identified three key biological pathways as candidates for the development of TGCTs (KIT, telomerase regulation, DMRT1) [14] . For example, KITLG has the strongest association for TGCT predisposition, identified in genome-wide association studies by a single nucleotide polymorphism at 12q22 within KITLG. This produced a 2.5-fold increased risk of disease per major allele. KIT signalling through the KRAS-MAPK pathway regulates migration and survival, and is upregulated in TGCTs [15] ; however, the significance of these risk alleles for developing relapse disease is not yet known. Although SGCT and NSGCT have been separately profiled [16, 17] , and other groups have used gene-set tools to predict response to platinum-based chemotherapy in advanced germ cell tumours [18, 19] , to our knowledge, no study has reported on expression profiles specific to relapsed clinical stage I TGCTs. Although a relapse signature was identified when combining all TGCTs using 10-or 30-probe sets, this effect was diluted when analysed according to individual histology, which is potentially related to sample size. Validation of these signatures in large external sets is required before this could be used in conjunction with standard pathological risk factors to identify a high-risk relapse group that would warrant adjuvant therapy. Furthermore, such signatures could detect a low-risk relapse population who may be monitored with a less intensive surveillance schedule.
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Notably, clear gene expression differences were identified that discriminated seminona from non-seminoma. For example, ERVWE1 (endogenous retrovirus group W envelope member 1) was associated with high fold change, which is in keeping with recent reports of elevated syncytin-1 (the glycoprotein encoded by endogenous retroviral loci) expression in SGCT samples [27] . Similarly, TCL1A, a family of oncoproteins that augment AKT signal transduction [12] , was upregulated in SGCTs [28] . Nevertheless, the diagnostic utility of TCL1 using immunohistochemistry remains unclear and has shown only variable results in its utility to discriminate between primary mediastinal seminoma and non-seminoma samples [29, 30] . The adaptor protein GRB7 has been identified as a differentiator of the seminoma from the non-seminoma phenotype [31] , but its gene was not associated with significant fold change in the present cohort.
The present study has several limitations. First, a highly selected heterogeneous clinical stage I TGCT cohort was included that that may not reflect the broader population of patients with clinical stage I TGCT. Given the small numbers Table 2 Top genes associated with delineating relapsed from nonrelapsed disease and seminoma from non-seminoma. and selective nature of the patient population, we could not determine whether the signature was independent of or complementary to traditional pathological risk factors or estimate the magnitude of additional risk conferred by the identified signature. Similarly, the clinical cut-off times for non-relapse in this study were 2 and 3 years for NSGCT and SGCT, respectively, given the well described timings of relapse [4, 7, 32] , although it is possible that late relapses could occur, thus diluting a potential genomic signal. Second, our cohort did not include matched normal testicular tissue as internal controls. Third, macro-dissection of the specimens may have included some normal tissue. Fourth, the lack of a validation cohort limits the generalizability of this gene signature, including patients with mature teratoma treated with primary retroperitoneal lymph node dissection. Further studies are planned, however, to confirm the present findings.
In conclusion, a discriminating signature for relapsed and non-relapsed clinical stage I TGCTs using 10 and 30 gene sets was identified, but this was not confirmed when SGCTs and NSGCTs were analysed separately. GSEA showed that, in relapsed patients, genes associated with active development and differentiation were enriched. Further studies are required to corroborate whether gene profiling may optimize standard pathological algorithms in predicting the risk of relapse for patients with clinical stage I TGCT.
